Background: Drug development in sarcoma has been hampered by the rarity and
heterogeneity of the disease and lack of predictive biomarkers to therapies. We assessed …

Aims Metaplastic breast carcinoma (MBC) is a rare subtype of breast carcinoma less
responsive to conventional chemotherapy than ductal carcinoma. In molecular terms, MBCs …

Background: Tumor mutational burden (TMB) is a predictive biomarker of response to
immune checkpoint inhibitors across multiple cancers. In Phase 1 of the TMB Harmonization …

3600 Background: The SWI/SNF complex includes proteins produced by 29 genes that
regulate chromatin structure remodeling through effects upon transcription, replication, and …

Title of Module/Lecture Page 1 Predictive biomarker profiling of > 1,900 sarcomas: Identification
of potential novel treatment modalities Sujana Movva1, Wenhsiang Wen2, Wangjuh Chen2 …

Background: PTEN is a tumor suppressor gene in signaling downstream of EGFR. Loss of
PTEN protein expression is one of the more common occurrences in human cancers, and its …

Background: Germline mutations in the tumor suppressor gene, BAP1, a deubiquitylase that
regulates key cellular pathways, are associated with a recently-described tumor …

e14585 Background: Challenges in patient accrual limit successful conduct of clinical trials
in rare gynecologic malignancies. A platform trial using molecular analysis to guide therapy …

Objective: The aim of this study was to determine whether enough actionable mutations exist
in rare gynecologic cancers to justify the design of a platform trial. Method: We compiled all …

Introduction: Immunohistochemical (IHC) analysis of protein expression in clinical
specimens has been invaluable in diagnosing, monitoring and guiding treatment in cancer …